Search results
Aurigene Pharmaceutical opens biologics facility in Hyderabad, India
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe process and analytical development laboratories at the facility are already operational, and the...
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating...
Benzinga· 2 days agoOSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant At the American Transplant Congress 2024 (June 1-5 Philadelphia) Nantes,
Invivyd aligns with FDA on rapid mAb trial pathway By Investing.com
Investing.com· 6 days agoInvivyd Inc. (NASDAQ: IVVD), a biopharmaceutical company, has announced an agreement with the U.S....
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
The Woonsocket Call· 3 days agoSyndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on June 1, 2024 the Company granted ...
Fauci faces skeptical GOP to bat back COVID-19 accusations - Roll Call
CQ Politics· 3 days agoLongtime government scientist Anthony Fauci pushed back against Republican accusations tying him to...
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND...
The Pendulum· 7 days ago...and Drug Administration (FDA) has acknowledged the company's resubmission of the Biologics License Application (BLA) for zolbetuximab, a first-in-class investigational claudin (CLDN) 18.2-targeted monoclonal antibody, for the first-line treatment of adults with locally advanced unresectable or...
ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
FierceBiotech· 2 days agoA new trend has emerged at this year’s American Society of Clinical Oncology conference: the...
The Push to Get More People Into Long COVID Studies
Medscape· 3 days agoWhen Ezra Spier was diagnosed with long COVID in late 2022, his main symptom, postexertional malaise, caused fatigue so severe that it forced him to quit...
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of...
Morningstar· 4 days agoGilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC-9 mCRC Study, Etrumadenant ...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 3 days agoIn May 2024, AstraZeneca signed a global licence and option agreement with Nona Biosciences for a...